ストックスクリーナーアプリを入手
14.32
0.59%
-0.10
アフターアワーズ：
14.40
0.08
+0.56%
前日終値:
$14.42
開ける：
$14.48
24時間の取引高:
2.71M
Relative Volume:
1.31
時価総額：
$2.04B
収益：
-
当期純損益:
$-45.61M
株価収益率:
-44.27
EPS:
-0.3235
ネットキャッシュフロー:
$-45.40M
1週間 パフォーマンス:
-0.86%
1か月 パフォーマンス:
-14.62%
6か月 パフォーマンス:
+28.11%
1年 パフォーマンス:
+56.67%
1日の値動き範囲:
$14.27
$14.77
1週間の範囲:
$14.00
$14.77
52週間の値動き範囲:
$8.99
$20.22
Trevi Therapeutics Inc Stock (TRVI) Company Profile
名前
Trevi Therapeutics Inc
セクター
電話
203-304-2499
住所
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.32 | 2.05B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
522.94 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
757.97 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
192.57 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.69 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.24 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-08-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-07-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 繰り返されました | Needham | Buy |
| 2025-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-30 | 開始されました | Raymond James | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-12 | 開始されました | B. Riley Securities | Buy |
| 2022-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | BMO Capital Markets | Outperform |
| 2019-06-03 | 開始されました | Needham | Buy |
| 2019-06-03 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | Stifel | Buy |
すべてを表示
Trevi Therapeutics Inc (TRVI) 最新ニュース
Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says - marketscreener.com
Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update By Investing.com - Investing.com Canada
Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update - Investing.com
Trevi Therapeutics stock trades at USD 14.71 as biotech data matters - AD HOC NEWS
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Biotechnology Innovator with an 85% Upside Potential - DirectorsTalk Interviews
Trevi Therapeutics Insider Sold Shares Worth $595,806, According to a Recent SEC Filing - marketscreener.com
Trevi Therapeutics (TRVI) director sells 39,473 shares under trading plan - Stock Titan
Trevi Therapeutics stock trades in a data vacuum as Haduvio moves toward Phase 3 - AD HOC NEWS
Trevi Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Director at Trevi Therapeutics (NASDAQ: TRVI) plans share sale after option exercise - Stock Titan
Trevi Therapeutics at cantor global healthcare conference: central cough bet By Investing.com - Investing.com Canada
BMO initiates coverage on Trevi Therapeutics at $36 - scanx.trade
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and ResistanceETF Outflow Streak - siam.in
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair Value - Yahoo Finance
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? - StockInvest.us
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Trevi Therapeutics Inc (TRVI) Peer Comparison – Compare with Others - Value Research
Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026 - Quiver Quantitative
Trevi Therapeutics to Participate in Upcoming September Conferences - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trevi Therapeutics Inc (TRVI) Key Financial Ratios – Valuation, Profitability & More - Value Research
EX-99.1 - SEC.gov
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 - Yahoo Finance
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
$Trevi Therapeutics (TRVI.US)$ lets punch through that BOLL band - Moomoo
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI - MarketBeat
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $28 - Moomoo
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
Trevi Therapeutics (TRVI) Short Interest & Short Float | Updated Aug 2026 $TRVI - MarketBeat
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
TRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.com
TREVI THERAPEUTICS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $24 - Bitget
Trevi Therapeutics Inc (TRVI) 財務データ
収益
当期純利益
現金流量
EPS
Trevi Therapeutics Inc (TRVI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Heffernan Michael Thomas | Director |
Sep 15 '26 |
Sale |
15.09 |
39,473 |
595,806 |
6,351 |
0.73%
0.62%
大文字化:
|
ボリューム (24 時間):